LOCAL NHS LOGO

AIR-NET: Testing anti-inflammatories for the treatment of bronchiectasis

A randomised, open-label, multifactorial, multicentre, platform trial using a range of repurposed anti-inflammatory treatment to improve outcomes in patients with bronchiectasis not due to cystic fibrosis, within the EMBARC international clinical research network.

Dear Colleague,

Your patient has kindly consented to join the AIR-NET Trial.

Patient details
Name: _____
DOB: _____

Address: _____
_____
_____

The AIR-NET trial is a multi-center open-label trial of repurposed anti-inflammatories in patients with bronchiectasis.

Patients with bronchiectasis who have the inflammatory marker neutrophil elastase in their sputum will be enrolled across the UK. AIR-NET is a platform trial, where patients will be randomised to receive either standard of care or one anti-inflammatory medication for 28 days. At the moment, there are 3 medications being tested but new treatment arms may be added, which means participants will continue to be recruited to this trial. A total of 42 participants will be allocated to take each treatment arm.

This patient has been randomised to receive: _____

The objective of the trial will be to evaluate the effect of a range of interventions compared to standard of care on the concentration of Neutrophil Elastase (NE) in sputum, assess the effect on bronchiectasis exacerbations and the effect on quality of life. Participants will attend trial visits over a 3-month period, with a treatment period of 28 days. Participants will also be seen if they have any exacerbations between these visits.

Patients will continue to take their usual medications without any changes before and during the trial duration. Participants will only be randomised to a treatment arm they are eligible for.

Trial exclusion medications:
To avoid contamination between the trial arms, participants who experience bronchiectasis exacerbations during the trial period should not be prescribed doxycycline. These should be treated with an alternative antibiotic.

Participants who are randomised to receive Dipyridamole must not be prescribed anti-coagulants or antithrombotic medications during the trial treatment period.

If any significant clinical findings are found during your patient's participation in this trial, you will be informed of the results and any relevant corrective action implemented by myself or medical colleagues.

If you have any questions, please do not hesitate to contact me.

Thank you for your assistance.

With kind regards,

[PI name]
[PI tel]
[PI email]